Business
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q3 2018
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q3 2018.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\nSun BioPharma, Inc. opens third site in Melbourne, Australia in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Patients with Metastatic Pancreatic CancerCompany announces leadership changesResults of new pancreatitis study presented at American Pancreatic Association meeting MINNEAPOLIS, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the quarter ended September 30, 2018.\n Front-Line Combination PDA StudyThe Company’s newest trial, a Phase 1a/1b combination of SBP-101 with gemcitabine and nab-paclitaxel in patients previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), continued to enroll patients in the quarter ended September 30, 2018.   The Phase 1a portion of this study will treat up to 18 PDA patients in three cohorts to determine a recommended dose of SBP-101 to be given in combination with standard treatment.  The Phase 1b portion will be an expansion at the recommended dose of SBP-101 and will guide SBP-101’s subsequent development for patients with PDA.  This multi-center, front-line study has 3 sites in Australia, The Austin Health Cancer Trials Centre in Melbourne, The Adelaide Cancer Centre in Adelaide, The Blacktown Cancer and Haematology Centre in Sydney and one site in the United States, The University of Florida Health Cancer Center in Gainesville, Florida. Suzanne Gagnon, MD, Chief Medical Officer for Sun BioPharma, Inc. commented, “We are delighted to have our Melbourne site open for this second study since Austin Health was the top enroller in our first-in-human study of SBP-101 monotherapy.  We continue to appreciate the hard work by all of our sites to get this second study enrolled expeditiously.” Leadership changes announced Effective October 31, 2018, Michael T. Cullen, MD, MBA, the company’s Executive Chairman, has accepted the additional responsibilities of President and CEO of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd. David Kaysen has resigned as President, CEO and Board member. These changes were the result of the need for ...